Palomar (PLMR) – Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Palomar (NASDAQ: PLMR) recently:

• 1/14/2026 – Palomar was upgraded by analysts at Weiss Ratings from a “hold (c+)” rating to a “buy (b-)” rating.
• 1/10/2026 – Palomar was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 1/7/2026 – Palomar had its price target raised by analysts at JPMorgan Chase & Co. from $145.00 to $155.00. They now have an “overweight” rating on the stock.
• 1/6/2026 – Palomar had its price target raised by analysts at Keefe, Bruyette & Woods from $170.00 to $171.00. They now have an “outperform” rating on the stock.
• 12/20/2025 – Palomar was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.

Insider Buying and Selling

In other Palomar news, insider Jonathan Knutzen sold 281 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $128.84, for a total value of $36,204.04. Following the completion of the transaction, the insider directly owned 21,565 shares in the company, valued at $2,778,434.60. This represents a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO T Christopher Uchida sold 782 shares of the firm’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $128.84, for a total transaction of $100,752.88. Following the sale, the chief financial officer owned 7,916 shares in the company, valued at $1,019,897.44. The trade was a 8.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 15,586 shares of company stock worth $1,999,706 over the last ninety days. 3.70% of the stock is owned by corporate insiders.

Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.